ChIP-exo Sequencing Service for High-Resolution Protein–DNA Binding Maps
Near-base-pair protein–DNA binding maps with sharper boundaries, lower background, and stronger signal-to-noise than conventional ChIP-seq.
Broad ChIP-seq peaks can hide adjacent binding events and leave the biologically relevant motif or boundary uncertain. This can make it difficult to distinguish alternative binding modes or select the right loci for downstream validation.
ChIP-exo adds exonuclease refinement to chromatin immunoprecipitation to narrow those boundaries. CD Genomics supports study design, wet-lab processing, sequencing, and ChIP-exo-aware bioinformatics in one coordinated service.
- Refine transcription factor and chromatin-protein binding locations
- Resolve strand-specific exonuclease-stop patterns and binding boundaries
- Connect high-resolution occupancy with motifs and regulatory annotations
- Extend projects with RNA-seq, ATAC-seq, or comparative epigenomic analysis
What Is ChIP-exo Sequencing?
ChIP-exo combines antibody-based chromatin immunoprecipitation with 5'-to-3' exonuclease digestion. After crosslinking, fragmentation, and immunoprecipitation, the exonuclease removes exposed DNA until it reaches a protein-protected boundary. Sequencing the resulting fragment ends generates paired, strand-aware signals that can localize protein-associated DNA more precisely than conventional ChIP-seq.
The assay is especially valuable when the biological question depends on the organization of a protein–DNA complex rather than the presence of enrichment alone. Published studies have used ChIP-exo to distinguish binding modes, examine motif-centered footprints, and map the relative positions of proteins within regulatory complexes. Resolution and usable signal remain dependent on antibody performance, target occupancy, sample quality, crosslinking, library complexity, sequencing depth, and the selected analysis model.
Best suited for
- Sequence-specific transcription factors with validated antibodies
- Closely spaced binding events within promoters or enhancers
- Motif-centered occupancy and alternative binding-mode analysis
- Spatial organization of chromatin-associated protein complexes
Consider another method when
- The primary need is broad histone-mark domain profiling
- Input is extremely limited and antibody compatibility is uncertain
- The study requires open-chromatin mapping rather than protein occupancy
- A conventional enrichment map already answers the research question
ChIP-exo Workflow
Our workflow is planned around the target protein, sample type, antibody evidence, and the resolution needed for interpretation. The exonuclease step is treated as a controlled refinement of immunoprecipitated DNA, not as a guarantee of single-nucleotide biological certainty.
1. Project and Antibody Review
We evaluate the biological question, reference genome, controls, replicate plan, antibody validation, and expected target abundance so feasibility risks can be addressed before sample submission.
2. Crosslinking and Chromatin Preparation
Protein–DNA complexes are stabilized and chromatin fragmentation is adapted to the submitted material, helping preserve comparable binding information across samples.
3. Immunoprecipitation
The target-associated chromatin is enriched with a validated antibody alongside the agreed input and controls, enabling signal to be interpreted against experimental background.
4. Exonuclease Refinement
Exposed DNA is digested toward crosslink-protected boundaries, concentrating informative fragment ends near protein-associated sites.
5. Library Preparation and Sequencing
Recovered DNA is converted into sequencing libraries, quality controlled, pooled, and sequenced using a project-matched design.
6. High-Resolution Analysis
Strand-aware signals are processed into binding events, motifs, annotations, comparative results, and report-ready visualizations.
Project-specific ChIP-exo workflow from feasibility review through boundary-aware analysis
Sample Requirements and Experimental Design
ChIP-exo success begins with recoverable target-bound chromatin. The following quantities are planning baselines rather than universal acceptance limits; final requirements are confirmed after the species, tissue composition, target abundance, antibody, and control design are reviewed.
| Material | Planning baseline | Key considerations |
|---|---|---|
| Cultured cells | Typically at least 2 × 10^7 cells per sample | Provide healthy, consistently handled cells; document treatment and harvest conditions. |
| Animal tissue | Typically at least 500 mg per sample | Rapid freezing and a consistent dissection strategy help preserve comparable chromatin states. |
| Plant tissue | Typically at least 1 g per sample | Species, tissue structure, secondary metabolites, and cell-wall disruption may affect feasibility. |
| Antibody | ChIP-validated antibody strongly preferred | Provide datasheet, lot, validation evidence, and a known positive locus when available. |
| Controls and replicates | Matched input required; at least two biological replicates | Three biological replicates are preferred for differential occupancy studies. |
Limited-input projects may be feasible for selected targets and sample types, but should be reviewed before collection. If antibody performance or input is the dominant constraint, CUT&Tag may offer a more suitable starting point.
Review Sample and Antibody FeasibilityChIP-exo Bioinformatics Analysis
ChIP-exo data require more than generic peak calling. Our analysis preserves strand information at fragment ends and connects footprint structure to sequence context, genes, and regulatory regions.
Sequencing configuration
| Item | Project configuration | Why it matters |
|---|---|---|
| Sequencing platform | Illumina short-read sequencing system | High-throughput sequencing supports strand-aware analysis of the informative ChIP-exo fragment ends. |
| Read configuration | Paired-end sequencing; read length finalized with the library design | Information from both fragment boundaries supports confident alignment and library-complexity assessment. |
| Recommended data amount | Customized to genome size, target abundance, expected occupancy, controls, and replicate design | Project-specific depth avoids applying one fixed number to both strong focal transcription-factor sites and weaker chromatin signals. |
| Primary analytical objective | Strand-specific 5' end profiling and high-resolution binding-event detection | The analysis converts sequence reads into interpretable boundaries, motifs, and regulatory annotations rather than a generic peak list. |
The exact instrument model, read length, and sequencing depth are confirmed during project design after the sample, antibody, reference genome, and control strategy have been reviewed.
Standard analysis
- Raw-read quality assessment and adapter processing to remove avoidable technical noise before interpretation
- Reference-genome alignment and library-complexity review to identify mapping or duplication concerns
- Strand-specific 5' end and exonuclease-stop profiles to visualize protected boundary geometry
- High-resolution binding-event detection to prioritize localized occupancy rather than broad enrichment alone
- Promoter, enhancer, gene-body, and intergenic annotation to connect binding events with regulatory context
- De novo and known-motif enrichment analysis to assess sequence preferences around localized events
- Metaprofiles, heatmaps, genome-browser tracks, and quality summaries for transparent review and figure development
Optional integrated analysis
- Differential binding across treatments, genotypes, or time points to identify condition-responsive occupancy
- Binding-mode and motif-centered footprint classification to separate alternative protein–DNA configurations
- Integration with RNA-seq to test occupancy–expression relationships
- Integration with ATAC-seq to place binding events in chromatin-accessibility context
- Cross-species conservation and orthologous regulatory analysis to evaluate shared regulatory architecture
- Custom transcription factor binding-site analysis for hypothesis-focused interpretation
Representative result types are shown conceptually; project figures depend on the target and study design
ChIP-exo Service Deliverables
Sequencing and Alignment Files
Quality-controlled FASTQ files, aligned BAM files, and normalized genome-browser tracks support transparent review and downstream reuse.
Binding and Footprint Results
Binding-event coordinates, strand-aware boundary profiles, annotated regions, motif results, and target-associated gene tables.
Interpretation Package
Quality metrics, figures, methods summary, analysis tables, and a final report organized around the research question.
Research Applications
Resolve how transcription factors occupy promoters, enhancers, and clustered regulatory motifs, and test whether perturbation changes binding position, intensity, or mode.
Examine the relative organization of DNA-associated proteins, cofactors, polymerases, and replication factors around protected boundaries.
Compare occupancy programs across differentiation, signaling, stress, or treatment conditions where closely spaced regulatory events may be functionally distinct.
Map transcription factor occupancy in plant tissues and connect high-resolution binding patterns with development, environmental response, and trait-associated regulatory regions.
Assess whether orthologous factors retain binding positions, motif preferences, or complex architectures across strains or species.
Combine precise protein occupancy with chromatin accessibility and gene expression to prioritize regulatory relationships for targeted validation.
Case Study: Mapping Replication-Origin Protein Architecture with ChIP-exo
ChIP-exo vs. ChIP-seq, CUT&RUN, and CUT&Tag
| Method | Primary strength | Typical interpretation | Important consideration |
|---|---|---|---|
| ChIP-exo | Exonuclease-refined, strand-aware boundaries | High-resolution protein-associated DNA and binding architecture | Requires strong immunoprecipitation and specialized analysis |
| ChIP-seq | Established genome-wide enrichment profiling | Broad to narrow occupancy regions, depending on target | Fragment size and background can limit positional precision |
| CUT&RUN | Targeted cleavage with low background | Protein occupancy with reduced bulk chromatin background | Nuclease accessibility and antibody performance shape signal |
| CUT&Tag | Efficient targeted tagmentation | Chromatin-protein or histone-mark profiling from relatively low input | Not designed to reproduce ChIP-exo exonuclease-stop architecture |
Best for: ChIP-exo is most useful when localized transcription-factor or chromatin-protein boundaries are central to the research question. Consider another method: for broad histone-mark domains, very limited input, or general enrichment mapping, ChIP-seq, CUT&RUN, or CUT&Tag may be more appropriate.
Method selection should follow the required biological resolution, sample constraints, and target type
Frequently Asked Questions
Plan a ChIP-exo Study Around the Binding Question
Share the target protein, species, sample type, available material, antibody evidence, experimental groups, and the biological decision the data must support. Our team will recommend a control, replicate, sequencing, and analysis plan aligned with the intended resolution.
Request a Project ReviewReferences
- Rhee HS, Pugh BF. Comprehensive genome-wide protein-DNA interactions detected at single-nucleotide resolution. Cell. 2011;147(6):1408–1419. DOI: 10.1016/j.cell.2011.11.013
- Rossi MJ, Lai WKM, Pugh BF. Simplified ChIP-exo assays. Nature Communications. 2018;9:2842. DOI: 10.1038/s41467-018-05265-7
- Biswas A, Narlikar L. Resolving diverse protein–DNA footprints from exonuclease-based ChIP experiments. Bioinformatics. 2021;37(Suppl 1):i367–i375. DOI: 10.1093/bioinformatics/btab274
- Bang I, Lee SM, Park S, et al. Deep-learning optimized DEOCSU suite provides an iterable pipeline for accurate ChIP-exo peak calling. Briefings in Bioinformatics. 2023;24(2):bbad024. DOI: 10.1093/bib/bbad024
- Reuter LM, Khadayate SP, Mossler A, et al. MCM2-7 loading-dependent ORC release ensures genome-wide origin licensing. Nature Communications. 2024;15:7306. DOI: 10.1038/s41467-024-51538-9
For research use only. Not for use in diagnostic procedures.